Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced the pricing of an underwritten public offering of 7,608,696 primary shares of its common ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE